Forbes: Teixobactin and iChip promise hope against antibiotic resistance
Forbes - 01/08/2015
Teixobactin is the first new class of antibiotic announced in decades. That news and even more importantly, the elegant way it was discovered, are the most exciting news I’ve seen in some time.
Antibiotic development has stagnated as pharmaceutical companies have instead turned their attention to the far more profitable ventures of drugs for chronic diseases, like diabetes or heart disease. Antibiotics had been relegated to the role of the unwanted stepchild, it seemed.